Investigation of spleen CXCR4 expression by [

CXCR4 Clinical studies Molecular imaging PET Pentixafor Retrospective studies Solid tumors Spleen Uptake

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
21 Aug 2021
Historique:
received: 07 06 2021
accepted: 07 08 2021
entrez: 21 8 2021
pubmed: 22 8 2021
medline: 22 8 2021
Statut: epublish

Résumé

The chemokine receptor CXCR4 is frequently overexpressed and associated with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently, CXCR4 molecular imaging using the CXCR4-specific positron emission tomography (PET) tracer Pentixafor ([ We investigated the hypothesis that enhanced spleen [ Spleen [

Sections du résumé

BACKGROUND BACKGROUND
The chemokine receptor CXCR4 is frequently overexpressed and associated with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently, CXCR4 molecular imaging using the CXCR4-specific positron emission tomography (PET) tracer Pentixafor ([
RESULTS RESULTS
We investigated the hypothesis that enhanced spleen [
CONCLUSION CONCLUSIONS
Spleen [

Identifiants

pubmed: 34417915
doi: 10.1186/s13550-021-00822-6
pii: 10.1186/s13550-021-00822-6
pmc: PMC8380222
doi:

Types de publication

Journal Article

Langues

eng

Pagination

77

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : SFB824, project C3
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB824, project Z1
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1335, project P3

Informations de copyright

© 2021. The Author(s).

Références

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10101-6
pubmed: 18632580
J Exp Med. 2004 Nov 1;200(9):1145-56
pubmed: 15520246
Nat Rev Immunol. 2018 Dec;18(12):773-789
pubmed: 30254251
Int J Cancer. 2012 Jun 15;130(12):2747-60
pubmed: 22261860
Blood. 2006 Mar 1;107(5):1761-7
pubmed: 16269611
N Engl J Med. 2012 Feb 16;366(7):610-8
pubmed: 22335738
Carcinogenesis. 2008 Aug;29(8):1483-92
pubmed: 18310089
Sci Rep. 2015 Apr 22;5:9800
pubmed: 25902419
Clin Cancer Res. 2015 Oct 1;21(19):4278-85
pubmed: 26199389
Cancer Imaging. 2021 Feb 12;21(1):22
pubmed: 33579381
J Nucl Med. 2016 May;57(5):741-6
pubmed: 26769866
Front Immunol. 2020 Jun 05;11:1126
pubmed: 32582203
Clin Cancer Res. 2005 Mar 1;11(5):1835-41
pubmed: 15756007
Clin Nucl Med. 2016 Apr;41(4):e204-5
pubmed: 26756098
Oncol Rep. 2018 Apr;39(4):2022-2030
pubmed: 29436696
Theranostics. 2017 Apr 5;7(6):1489-1498
pubmed: 28529632
Cancer Immunol Immunother. 2020 Jul;69(7):1265-1277
pubmed: 32170377
Immunity. 2010 Jun 25;32(6):790-802
pubmed: 20605485
Oncotarget. 2017 May 27;8(57):96732-96737
pubmed: 29228566
Front Oncol. 2019 Aug 14;9:770
pubmed: 31475113
Oncotarget. 2015 Mar 10;6(7):5022-40
pubmed: 25669980
Oncotarget. 2016 Feb 23;7(8):9288-95
pubmed: 26843617
Clin Cancer Res. 2005 Dec 1;11(23):8273-80
pubmed: 16322285
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Dev Cell. 2015 May 26;33(4):455-68
pubmed: 26017770
Thromb Haemost. 2003 Jun;89(6):1098-106
pubmed: 12783124
Clin Nucl Med. 2017 Jan;42(1):e29-e34
pubmed: 27819856
Cancer. 2001 Jun 15;91(12):2214-21
pubmed: 11413508
J Nucl Med. 2020 Dec;61(12):1765-1771
pubmed: 32332145
Cell Death Dis. 2017 May 25;8(5):e2832
pubmed: 28542132
Haematologica. 2016 Aug;101(8):932-40
pubmed: 27175029
EMBO Mol Med. 2015 Mar 03;7(4):477-87
pubmed: 25736399
Thromb Res. 2010 Aug;126(2):113-8
pubmed: 20684071
Nat Rev Cancer. 2004 Jul;4(7):540-50
pubmed: 15229479
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2491-6
pubmed: 22308361
Cell Rep. 2012 Sep 27;2(3):628-39
pubmed: 22959433
Ann Oncol. 2016 Nov;27(11):2067-2074
pubmed: 27502717
Immunity. 2013 Feb 21;38(2):296-308
pubmed: 23333075
Immunity. 2013 Nov 14;39(5):806-18
pubmed: 24238338
Blood. 2001 Nov 1;98(9):2720-5
pubmed: 11675343
Sci Rep. 2019 Feb 20;9(1):2399
pubmed: 30787324
Theranostics. 2017 Jan 1;7(1):205-212
pubmed: 28042328
Acta Oncol. 2015 Jul;54(7):961-70
pubmed: 25984930
J Med Chem. 2011 Nov 10;54(21):7648-62
pubmed: 21905730
Int Immunopharmacol. 2019 Oct;75:105818
pubmed: 31437795
Front Immunol. 2017 Sep 29;8:1225
pubmed: 29085358
Stem Cells. 2015 Aug;33(8):2391-9
pubmed: 25966814
Cancer Cell. 2018 Jun 11;33(6):965-983
pubmed: 29657130
PLoS One. 2018 Aug 23;13(8):e0202555
pubmed: 30138391
J Clin Invest. 2018 Aug 1;128(8):3425-3438
pubmed: 29771686
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
Cell. 2017 Jan 26;168(3):487-502.e15
pubmed: 28111070
Cancer Microenviron. 2009 Dec;2(1):1-7
pubmed: 19308676

Auteurs

Richard Lewis (R)

Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.

Stefan Habringer (S)

Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Berlin Institute of Health (BIH), Berlin, Germany.

Malte Kircher (M)

Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.

Maike Hefter (M)

Clinic and Policlinic for Internal Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.

Caroline Anna Peuker (CA)

Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.

Rudolf Werner (R)

Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany.

Valëza Ademaj-Kospiri (V)

Clinic for Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.

Alexander Gäble (A)

Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.

Wolfgang Weber (W)

Clinic for Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.

Hans-Jürgen Wester (HJ)

Chair of Pharmaceutical Chemistry, Technical University of Munich, Garching, Germany.

Andreas Buck (A)

Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany.

Peter Herhaus (P)

Clinic and Policlinic for Internal Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.

Constantin Lapa (C)

Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.

Ulrich Keller (U)

Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. ulrich.keller@charite.de.
German Cancer Consortium (DKTK), Partner Site Berlin; and German Cancer Research Center (DKFZ), Heidelberg, Germany. ulrich.keller@charite.de.
Max-Delbrück-Center for Molecular Medicine, Berlin, Germany. ulrich.keller@charite.de.

Classifications MeSH